Myfortic vs. Cellcept in Kidney Transplant Recipients
Status:
Completed
Trial end date:
2006-02-01
Target enrollment:
Participant gender:
Summary
The comparison the incidence of G.I. toxicity between Myfortic® vs. Cellcept® in 150
sequential patients, in which 75 will be randomized to Cellcept® and 75 to Myfortic® in first
and second living or deceased donor renal transplant recipients.